v3.26.3
Notes to the unaudited interim condensed consolidated statement of (income) loss - Investment in Hepalys is accounted for using the equity method (Details) - EUR (€)
€ in Thousands
6 Months Ended 12 Months Ended
Feb. 24, 2026
Jan. 14, 2026
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Investments accounted for using the equity method          
Non-current assets     € 5,244   € 5,042
Current assets     245,966   244,469
Total assets     251,210   249,511
Shareholders' equity     59,002 € (8,909) (28,522)
Current liabilities     64,588   77,378
Equity and liabilities     251,210   249,511
Balance at the beginning     (28,522) (106,647) (106,647)
Net loss for the period     (69,467) (175,882)  
Other comprehensive income     (102) (167)  
Balance at the end     59,002 € (8,909) (28,522)
Carrying amount     € 528   € 527
Hepalys Pharma, Inc          
Investments accounted for using the equity method          
Group's share in % 13.68% 13.92% 13.68% 15.00% 14.64%
Group's share     € 1,832   € 1,869
Elimination of unrealized profit on downstream sales     (1,340)   (1,378)
Goodwill     37   37
Carrying amount     528   527
Hepalys Pharma, Inc          
Investments accounted for using the equity method          
Non-current assets     11,556   12,729
Current assets     1,966   183
Total assets     13,522   12,912
Shareholders' equity     13,389   12,766
Current liabilities     133   146
Equity and liabilities     13,522   12,912
Balance at the beginning     12,766 € 18,368 18,368
Net loss for the period     (1,642) € (2,158) (3,816)
Other comprehensive income     (70)   (1,786)
Capital variations     2,335    
Balance at the end     € 13,389   € 12,766